Risk Stratification of Pancreatic Cysts According to Their Malignant Potential Using Integrated Molecular Pathology
Integrated molecular pathology correctly identifies those patients at very low risk of developing pancreatic cancer (NPV=97%).
Patients diagnosed as “statistically higher risk” have a 31-fold increased risk of cancer compared to “benign” and “statistically indolent” patients.
(HR=30.8 [95% CI: 15.4-61.9, p<.0001])
Patients diagnosed as “aggressive” have a 76-fold increased risk of cancer compared to “benign” or “statistically indolent” patients.
(HR=76.3 [95% CI: 36.4-159.9, p<.0001])